BIOMARIN PHARMACEUTICAL INC Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax of $0 for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-28.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax · last filed 2019-02-28
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for the quarter ending 2014-12-31 was $738.00K.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for the quarter ending 2014-09-30 was $203.00K, a 463.89% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for the quarter ending 2014-06-30 was $256.00K, a 91.04% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for the quarter ending 2014-03-31 was $320.00K, a 78.77% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for fiscal 2018 was $0.00.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for fiscal 2017 was $0.00.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for fiscal 2016 was $0.00.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
| Period end | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax 3 month | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax 3 month as first filed | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax 6 month | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax 6 month as first filed | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax 9 month | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax 12 month | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2018-12-31 | $0.00 10-K · filed 2019-02-28 | ||||||
| 2017-12-31 | $0.00 10-K · filed 2019-02-28 | ||||||
| 2016-12-31 | $0.00 10-K · filed 2019-02-28 | ||||||
| 2015-12-31 | $0.00 10-K · filed 2018-02-26 | ||||||
| 2014-12-31 | $738.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $941.00K derived: sum of 2 quarters · filed 2017-02-27 | $1.20M derived: sum of 3 quarters · filed 2017-02-27 | $365.00K 10-K · filed 2017-02-27 | -$365.00K 10-K · filed 2015-03-02 | ||
| 2014-09-30 | $203.00K 10-Q · filed 2015-11-02 | $459.00K derived: sum of 2 quarters · filed 2015-11-02 | -$373.00K 10-Q · filed 2015-11-02 | $458.00K derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-06-30 | $256.00K 10-Q · filed 2015-08-05 | -$256.00K 10-Q · filed 2014-07-31 | $576.00K 10-Q · filed 2015-08-05 | -$576.00K 10-Q · filed 2014-07-31 | $255.00K derived: sum of 3 quarters · filed 2016-02-29 | $291.00K derived: sum of 4 quarters · filed 2016-02-29 | |
| 2014-03-31 | $320.00K 10-Q · filed 2015-05-05 | -$320.00K 10-Q · filed 2014-05-02 | -$1.00K derived: sum of 2 quarters · filed 2016-02-29 | $35.00K derived: sum of 3 quarters · filed 2016-02-29 | $169.00K derived: sum of 4 quarters · filed 2016-02-29 | ||
| 2013-12-31 | -$321.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | -$285.00K derived: sum of 2 quarters · filed 2016-02-29 | -$151.00K derived: sum of 3 quarters · filed 2016-02-29 | $28.00K 10-K · filed 2016-02-29 | |||
| 2013-09-30 | $36.00K 10-Q · filed 2014-10-28 | $170.00K derived: sum of 2 quarters · filed 2014-10-28 | $349.00K 10-Q · filed 2014-10-28 | ||||
| 2013-06-30 | $134.00K 10-Q · filed 2014-07-31 | $313.00K 10-Q · filed 2014-07-31 | |||||
| 2013-03-31 | $179.00K 10-Q · filed 2014-05-02 | ||||||
| 2012-12-31 | $2.15M 10-K · filed 2015-03-02 | -$2.15M 10-K · filed 2014-02-26 | |||||
| 2011-12-31 | $1.65M 10-K · filed 2014-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |